MedTrace Logo

Boosted Atazanavir and Truvada Given Once-Daily - BATON Study

NCT00224445 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2013-01-10

No results posted yet for this study

Summary

To determine the safety and efficacy of a simple, once-daily antiretroviral (ARV) regimen consisting of a fixed-dose combination tablet containing Truvada combined with atazanavir boosted with ritonavir in treatment naive patients.

Conditions

  • HIV Infections

Interventions

DRUG

Truvada

Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet) administered orally once daily (QD)

DRUG

Atazanavir

Atazanavir 300 mg (given as two 150-mg capsules) administered orally QD

DRUG

Ritonavir

Ritonavir 100 mg capsule administered orally QD

Sponsors & Collaborators

Principal Investigators

  • John Flaherty · Gilead Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00224445 on ClinicalTrials.gov